Search by Drug Name or NDC
NDC 49702-0255-37 Tivicay PD 5 mg/1 Details
Tivicay PD 5 mg/1
Tivicay PD is a ORAL TABLET, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is DOLUTEGRAVIR SODIUM.
MedlinePlus Drug Summary
Dolutegravir is used with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 4 weeks of age and older who weigh at least 6.6 lbs (3 kg). It is also used in combination with rilpivirine (Edurant) to treat HIV in certain adults to replace their current HIV medication(s) that has been taken for at least 6 months. Dolutegravir is in a class of medications called HIV integrase inhibitors. It works by decreasing the amount of HIV in your blood and increasing the number of immune cells that help fight infections in your body. Although dolutegravir does not cure HIV, using it along with other medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0255-37Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dolutegravir
Product Information
| NDC | 49702-0255 |
|---|---|
| Product ID | 49702-255_a7af7500-2f34-45cc-bcb9-0fbf4655880a |
| Associated GPIs | 12103015107320 |
| GCN Sequence Number | 081177 |
| GCN Sequence Number Description | dolutegravir sodium TAB SUSP 5 MG ORAL |
| HIC3 | W5U |
| HIC3 Description | ANTIVIRALS,HIV-1 INTEGRASE STRAND TRANSFER INHIBTR |
| GCN | 48218 |
| HICL Sequence Number | 040533 |
| HICL Sequence Number Description | DOLUTEGRAVIR SODIUM |
| Brand/Generic | Brand |
| Proprietary Name | Tivicay PD |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | dolutegravir sodium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FOR SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 5 |
| Active Ingredient Units | mg/1 |
| Substance Name | DOLUTEGRAVIR SODIUM |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA213983 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0255-37 (49702025537)
| NDC Package Code | 49702-255-37 |
|---|---|
| Billing NDC | 49702025537 |
| Package | 1 BOTTLE in 1 CARTON (49702-255-37) / 60 TABLET, FOR SUSPENSION in 1 BOTTLE |
| Marketing Start Date | 2020-06-12 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |